<DOC>
	<DOCNO>NCT02054351</DOCNO>
	<brief_summary>Advanced ovarian cancer high medical need indication . Cure available patient treatment palliative intent . A proportion advanced stage ovarian cancer express substantial level Claudin 6 ( CLDN6 ) , carcino-embryonic transmembrane protein , absent normal adult human tissue . IMAB027 monoclonal antibody bind CLDN6 . Preclinically IMAB027 show inhibit tumor growth kill cancer cell antibody-dependent cellular cytotoxicity complement-dependent cytotoxicity . This trial first-in-human dose escalation dose find Phase 1 trial IMAB027 patient recurrent advance ovarian cancer ass safety tolerability , pharmacokinetics , antitumoral activity immunogenicity IMAB027 .</brief_summary>
	<brief_title>Phase 1 Trial IMAB027 Patients With Recurrent Advanced Ovarian Cancer ( OVAR )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Female patient ≥18 year age , upper age limit 3 . Histologically cytologically confirm CLDN6+ ovarian cancer histology type include primary peritoneal fallopian tube tumor ( histological documentation original primary tumor require via pathology report ) 4 . Performance status ECOG 02 5 . Patients measurable , nonmeasurable , evaluable disease : Evaluable disease : define confirm CA125 ≥2 x ULN , Measurable disease ( RECIST 1.1 ) : define least one lesion accurately measure least one dimension 6 . Availability FFPE tumor tissue sample tumor cell positive paracentesis fluid sample ( abdominal pleural cavity ) assessment CLDN6 positivity 7 . Life expectancy &gt; 12 week 8 . Adequate organ function define : Adequate hematologic function ( ANC ≥1000/μl , platelets ≥100.000/μl , hemoglobin ≥9.0 g/dl ( post transfusion ) ) ; Adequate renal function ( serum creatinine ≤1.5 mg/dl [ 114.5 μmol/l ] creatinine clearance rate ≥30 ml/min ) ; Adequate liver function ( serum total bilirubin ≤2 x ULN , AST/ALT ≤3 x ULN ) 9 . Patients childbearing potential must negative βHCG urine test within 72 hour receive treatment 1 . Patient pregnant breastfeeding 2 . Prior allergic reaction intolerance monoclonal antibody ( humanize chimeric ) 3 . Any prior antitumor therapy within 14 day prior start IMAB027 treatment 4 . Other concurrent anticancer therapy 5 . HIV infection medical history active Hepatitis B C infection require treatment 6 . History one follow cardiovascular condition within past 6 month : Myocardial infarction ( TWave/NonTWave ) , Unstable angina pectoris Class II , III IV congestive heart failure define New York Heart Association ( NYHA ) , History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) . Patients recent DVT treat therapeutic anticoagulant agent ( exclude warfarin ) least 6 week eligible 7 . Other investigational agent device concurrently within 14 day start IMAB027 treatment 8 . Any hemoptysis bleeding event clinically relevant within 2 week first dose study drug 9 . Clinical symptom brain metastasis tumorassociated spinal cord compression 10 . Need continuous , systemic immunosuppressive therapy 11 . Any medical condition would , opinion Investigator , limit patient 's ability complete study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced ovarian cancer</keyword>
	<keyword>CLDN6 positive</keyword>
</DOC>